To become a preferred drug discovery partner globally thereby contributing positively to the life of patients.
To become the most valued Pharma partner to the World Pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products that comply with the highest regulatory standards.
Chief Executive Officer
- Established leader with >20 years of experience working with global large Pharma.
- Filed innovative NDA/ANDA/505(b)(2) products through efficient regulatory pathway.
- Involved in development and filing for >150 products in different regulated markets including USA and EU.
- Established highly efficient CRO and CDMO model for US and EU markets to provide end-to-end solution across various stages of drug discovery.
- Overseeing the business activity and managing a task force of >80 scientists which includes organic chemists, analytical chemists and formulation scientists.
Chief Scientific Officer
- Ph.D. in Medicinal Chemistry and Postdoc in the field of in silico drug design from Institute of Organic Chemistry and Biochemistry, Prague
- Managed and directed a work force of almost 45 scientists working on FTE, FFS and risk-share projects for clients based out of USA, UK, Europe and Asia.
- Managed cross-functional discovery projects where he has been a key contributor right from inception of the project on several therapeutic areas like pain, oncology, CNS disorders and orphan diseases.
- Received several awards in his career from agencies like CSIR, INSA, GUJCOST, European Atherosclerosis Society (EAS), and World Academy of Science, Engineering and Technology (WASET).
- Co-authored over 30 peer-reviewed publications, patents, abstracts and book chapters and has presented at several international conferences.